MYUNGMOON Pharm co.,Ltd

KSE 017180.KS

MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments for the year ending December 31, 2023: USD 8.96 M

MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments is USD 8.96 M for the year ending December 31, 2023, a 13.58% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments for the year ending December 31, 2022 was USD 7.89 M, a -10.39% change year over year.
MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments for the year ending December 31, 2021 was USD 8.80 M, a -26.74% change year over year.
MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments for the year ending December 31, 2020 was USD 12.01 M, a 64.26% change year over year.
MYUNGMOON Pharm co.,Ltd Cash and Short-Term Investments for the year ending December 31, 2019 was USD 7.31 M, a -9.18% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KSE: 017180.KS

MYUNGMOON Pharm co.,Ltd

CEO	Mr. Kyu-Huok Lee
IPO Date	July 10, 2008
Location	South Korea
Headquarters	7, Gangnam-daero
Employees	281
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Dental Care Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food

Description

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years